新华财经长沙12月2日电（记者常竣斐）"十五五"规划建议提出，推动量子科技、生物制造、氢能和核 聚变能、脑机接口、具身智能、第六代移动通信等成为新的经济增长点。记者在12月1日举办的津市市 院士专家咨询委员会第三次会议暨生物制造产业创新大会上观察到，湖南津市已聚集27家生物制造核心 企业，可生产200多种高端合成生物产品，科创企业涌入，生物制造产业正加速转型升级。 慕恩（广州）生物科技有限公司2018年入选了津市市政府与广州越秀基金以"政府+基金"联合投资方式 开展的企业"育苗计划"，2020年签约落户津市后成立湖南慕恩生物科技有限公司。目前已搭建起从发现 微生物、筛选微生物、改造微生物到应用微生物的完整微生物组产业化技术体系，并成长为国际领先的 微生物组平台型技术公司，建成超32万株微生物菌种资源库。 据介绍，津市坚持"飞地研发+津市制造"，构建"科创平台—中试基地—加速工厂—产业园区"生物制造 全链条孵化体系。2023年，湖南生物制造中试基地有限公司成立，可协助企业完成氨基酸类产品、维生 素类产品和化妆类产品的中试试验，最多可同时为5个科研团队完成产品验证，今年11月入围了工信部 公示的首批生物制造中试能 ...

Group 1 - The company currently offers inositol as its vitamin product and plans to launch additional vitamin and amino acid products in the future [1]

Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, with revenue at 1.588 billion yuan, down 11.81% year-on-year, and net profit plummeting 65.28% to 49.3 million yuan [1] Financial Performance - Revenue for the first half of 2025 was 1.588 billion yuan, reflecting an 11.81% decrease compared to the previous year [1] - Net profit fell sharply by 65.28%, amounting to 49.3 million yuan [1] - Operating cash flow decreased from 316 million yuan in the same period last year to 2 million yuan, a decline of 93.6% [1] - Accounts receivable surged by 92.6% to 561 million yuan, representing 27% of current assets, indicating worsened sales collection efficiency [1] Factors Affecting Performance - The decline in revenue and profit was primarily due to intensified competition in the international market and the impact of drug price negotiations, leading to reduced sales and profit margins for core products [1] - Key product categories, including steroid hormones and amino acids, experienced revenue declines, with amino acid product revenue down by 9.01% and other categories down by 22.09%, including a 22.01% drop in formulation revenue [1] - The company faced a significant financial penalty due to antitrust issues, resulting in a total fine and confiscation of illegal gains amounting to 69.1924 million yuan, which was recorded as an extraordinary expense, causing a 31,905.46% year-on-year increase in such expenses [1] Research and Development - In line with cost-cutting strategies, the company's R&D expenses decreased by 24.65% to 63.17 million yuan [2] - Despite the reduction in R&D spending, the company successfully obtained approval for three new drugs, including a treatment for respiratory diseases [2]